Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles
Authors:
Open Access
- 1 June 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 14 (6) , 1426-1430
Abstract
The luteal phase hormonal profile and the clinical outcome of 69 patients undergoing in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) after ovarian stimulation with human menopausal gonadotrophin (HMG) and the gonadotrophin-releasing hormone (GnRH) antagonist Cetrorelix were analysed. Twenty-four patients received Cetrorelix 0.5 mg (group I) while in 45 patients Cetrorelix 0.25 mg was administered (group II). Human chorionic gonadotrophin (HCG) was used as luteal support. Nine clinical pregnancies were obtained in group I (37.5%) and 12 in group II (26.6%). These results were not significantly different. Serum progesterone and oestradiol concentrations did not differ between the two groups either in pregnant or non-pregnant patients. An expected decrease of the same hormones was observed 8 days after the pre-ovulatory HCG injection in non-pregnant women. With regard to serum luteinizing hormone concentrations, a decrease was observed 2 days after the pre-ovulatory HCG injection and was maintained at almost undetectable levels throughout the entire luteal phase in both conception and non-conception cycles of group I and group II. This study demonstrates that different doses of GnRH antagonist do not have any impact on the luteal phase of IVF/ICSI cycles when hormonal support is given.Keywords
This publication has 34 references indexed in Scilit:
- The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist CetrorelixFertility and Sterility, 1998
- Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulationFertility and Sterility, 1997
- Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulationHuman Reproduction, 1994
- The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal womenAmerican Journal of Obstetrics and Gynecology, 1991
- Efficacy of progesterone support in the luteal phase following in-vitro fertilization and embryo transfer: meta-analysis of clinical trialsHuman Reproduction, 1988
- Characterizing pituitary response to a gonadotropin-releasing hormone (GnRH) antagonist in monkeys: tonic follicle-stimulating hormone/luteinizing hormone secretion versus acute GnRH challenge tests before, during, and after treatmentFertility and Sterility, 1987
- Specific Binding of Gonadotrophin-Releasing Hormone and an Agonist to Human Corpus Luteum Homogenates: Characterization, Properties, and Luteal Phase Levels*The Journal of Clinical Endocrinology & Metabolism, 1985
- The effect of luteinizing hormone-releasing factor and its agonist on cultured human granulosa cellsFertility and Sterility, 1982
- Gonadotropin-Releasing Hormone Receptors: Characterization, Physiological Regulation, and Relationship to Reproductive FunctionEndocrine Reviews, 1981
- Induction of Luteolysis in the Human with a Long-Acting Analog of Luteinizing Hormone-Releasing FactorScience, 1979